Page 4 of 5 · 111 questions tagged cardiovascular.
What I have: SELECT · dulaglutide. I can parse the result. I am less sure what it licenses me to conclude. I have deliberately not looked at anyone else’s…
What I am working with: SOUL · a GLP-1 receptor agonist. I would like help reading this properly rather than being told what conclusion to reach. I have the full…
Setup, so nobody has to ask: TRIUMPH-1 · cagrilintide. I have read the primary source rather than the summary, which has left me with more questions. I understand the…
Numbers first: FLOW · orforglipron. This is presented as though it settles something, and I am not convinced it does. I have two documents that appear to disagree,…
What I am working with: SURPASS-3 · cagrilintide. I would like help reading this properly rather than being told what conclusion to reach. I have the full report…
What I have: STEP 2 · retatrutide. This is presented as though it settles something, and I am not convinced it does. I have two documents that appear to disagree,…
Setup, so nobody has to ask: SELECT · a GLP-1 receptor agonist. I have read the primary source rather than the summary, which has left me with more questions. I…
I have three data points across nine months, which I hope is enough to see a trend. This should be a straightforward calculation and I keep getting two different…
Numbers first: TRIUMPH-3 · dulaglutide. This is presented as though it settles something, and I am not convinced it does. I have two documents that appear to…
I have the full paper rather than the abstract, and the supplementary appendix. I have the document in front of me and I can read the numbers. What I cannot do is…
I am reading the trial table rather than the press release, which is why the numbers differ. I can do the algebra. I am not confident about the conversion factors. If…
Setup, so nobody has to ask: TRIUMPH-3 · a GLP-1 receptor agonist. I would like help reading this properly rather than being told what conclusion to reach. I have the…
The case in front of me: SELECT · tirzepatide. The figures are clear enough; the question is what they mean and what they do not. I can supply the numbers if the…
Numbers first: STEP 8 · dulaglutide. This is presented as though it settles something, and I am not convinced it does. I have two documents that appear to disagree,…
This is a question about interpretation, not about whether to act — I will take action questions elsewhere. Please show the division. I want to check my own against…
For reference: SURMOUNT-OSA · survodutide. I want to understand what this actually establishes, as opposed to what it is being used to imply. My concern is that I am…
I have three data points across nine months, which I hope is enough to see a trend. I would like the arithmetic checked rather than the conclusion asserted. I have…
The particulars: STEP 2 · semaglutide. I have the document in front of me and I can read the numbers. What I cannot do is interpret them. I am reasonably comfortable…
The case in front of me: SURMOUNT-1 · tirzepatide. The figures are clear enough; the question is what they mean and what they do not. I can supply the numbers if the…
Stated plainly: STEP 2 · cagrilintide. I have read the primary source rather than the summary, which has left me with more questions. I understand the headline. I do…
The case in front of me: PIONEER-1 · liraglutide. I would like to know the limits of what can be inferred from this. What I am trying to avoid is over-reading a…
Numbers first: ATTAIN-1 · dulaglutide. This is presented as though it settles something, and I am not convinced it does. I have two documents that appear to disagree,…
I have three data points across nine months, which I hope is enough to see a trend. I would like the arithmetic checked rather than the conclusion asserted. I have…
Conditions: SURMOUNT-3 · liraglutide. The figures are clear enough; the question is what they mean and what they do not. I can supply the numbers if the specifics…